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Abstract
Background: People with MS may have unique perspectives on COVID-19 vaccines due to their condition and/or medications.
Objective: Assess perspectives and experiences with COVID-19 vaccination, and quantify variables
impacting COVID-19 vaccine willingness in people with MS.
Methods: A survey captured demographics, MS characteristics, and COVID-19 infection and exposures
data; opinions on COVID-19 vaccine safety, side effects, and efﬁcacy; and experiences following vaccination. Chi-square tests and a logistic regression model were used to denote between-group differences and
variables predicting vaccine willingness, respectively.
Results: Most (87.8%) of the 237 participants were willing to receive the vaccine. Fifteen percent held or
delayed a DMT dose for vaccination. MS symptoms worsened in a minority (7.6% ﬁrst/only dose; 14.7%
second dose), and most side effects were mild (80.0%; 55.3%). Those not planning to receive the vaccine
were primarily concerned with long-term safety (70.4%). Medical comorbidities (adjusted odds ratio
[aOR]=5.222; p=0.04) and following infection prevention precautions (aOR=6.330; p=0.008) were associated with vaccine willingness.
Conclusion: Most individuals with MS surveyed plan to receive the COVID-19 vaccine. People with MS
experience similar side effects to the general population, and few experience transient MS symptom worsening. These results can inform conversations on vaccination between providers and people with MS.
Keywords: Multiple sclerosis, COVID-19, vaccine
Date received: 10 September 2021; accepted 16 February 2022

Background
Multiple sclerosis (MS) is an immune-mediated
demyelinating and neurodegenerative disease of
the central nervous system (CNS), with an estimated prevalence in the United States of over
600,000 people.1 MS onset tends to occur in
early adulthood and often requires chronic treatment.2 Most people with MS are treated with
disease-modifying therapies (DMTs) that can
limit relapses and accrual of neurologic disability.3
The coronavirus disease 2019 (COVID-19) pandemic poses signiﬁcant challenges to the long-term
management of people with MS.4,5,6 Emerging
data suggest that some DMTs, in particular those
with immunosuppressive properties, may negatively impact outcomes of COVID-19 in people

with MS,7 although the effect of those DMTs on
risk of COVID-19 is less certain.8,9
Several highly efﬁcacious vaccines have been developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for
COVID-19, but vaccine hesitancy remains an obstacle.10 In addition, many people with MS are understandably anxious as to how MS or their DMT
impact the safety and efﬁcacy of the COVID-19 vaccines.11 Concern over the effect of vaccines on MS
relapses persist despite research disproving the link
between vaccination and MS.12,13 Studies conducted
at various timepoints during the COVID-19 pandemic
suggested that 7-15% of people with MS were unwilling to get a COVID-19 vaccine.11,14 The COVID-19
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vaccines can also cause systemic side effects, such as
fever, that can transiently worsen MS symptoms.15
COVID-19 vaccine safety in people with MS has
been supported by expert organizations such as the
National MS Society (NMSS) in the United States16
and internationally.17 Regarding vaccine efﬁcacy,
several studies have shown that some DMTs are associated with a reduced humoral immune response to
existing vaccines,18,19 and emerging data suggest
that this paradigm extends to the COVID-19
vaccines.20,21
In this study, we ﬁrst aim to evaluate the attitudes of
people with MS towards the COVID-19 vaccines. We
will additionally present the collective experiences of
individuals within this cohort who have received at
least one dose of a COVID-19 vaccine.

Methods
This is a prospective, observational, single-cohort
study assessing patient-reported opinions and experiences with COVID-19 vaccines in people with MS.
This project leverages data from the COVID-19 and
Multiple Sclerosis survey-based registry at
Washington University in St. Louis, Missouri,
which was originally developed in collaboration
with Cleveland Clinic and Johns Hopkins
University. This study captures details from people
with MS regarding their exposures to/experiences
with COVID-19. This study is currently active, and
over 300 participants are already enrolled. People
with MS are invited to participate by verbal invitation
at clinic visits, by telephone, or by messages through
the electronic medical record. Participants in this
study complete periodic surveys online: after completing a baseline survey, participants complete
follow-up surveys every two weeks for the ﬁrst
three months, and monthly follow-up surveys thereafter for up to one year. Data are collected and
managed using REDCap, a secure web-based software platform designed to support data capture for
research studies.22,23 Enrollment in the registry
began on September 17, 2020; a section of survey
questions regarding COVID-19 vaccination was
added to follow-up surveys on March 24, 2021. The
data were censored on May 26, 2021.
All participants in the registry meeting the inclusion
criteria were included in this analysis. Individual
respondents were conﬁrmed to be patients with a clinical diagnosis of MS followed at the tertiary care MS
subspecialty outpatient clinic at Washington
University, at which all people with MS are
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encouraged to get a COVID-19 vaccine when it is
available to them in accordance with NMSS
guidance.16
Patient-level variables collected in this survey study
include demographics; comorbidities applicable to
COVID-19 such as hypertension, COPD, diabetes,
and smoking status; employment status; MS characteristics such as subtype (per neurologist assessment
in the medical record), date of last relapse, and
which DMT they are treated with (as well as
whether any alterations in dosing regimen were
made); clinical information on any COVID-19 infection/exposures, if applicable; and behavioral modiﬁcations in response to the pandemic. Participants are
also asked to report subjective and objective data on
COVID-19 vaccines, such as whether they have
received or are planning to receive the vaccine,
whether they have concerns about vaccine safety/
side effects/efﬁcacy, and, if so, what those concerns
are. If they have already received a COVID-19
vaccine, participants report the vaccine date/manufacturer, whether they experienced side effects or MS
symptom worsening, what those side effects were,
how long they lasted, and how severe they were.
Descriptive statistics are used to report COVID-19
vaccine perspectives and experiences of study participants. For some comparative analyses, respondents
are categorized, such as those taking DMTs expected
to have a large impact on humoral vaccine responses
(i.e., B cell depleting monoclonal antibodies, sphingosine 1-phosphate [S1P] receptor modulators),19,24
denoted as “high-risk,” vs. DMTs expected to have
a low impact, denoted as “low-risk;” those with and
without medical comorbidities; and those with and
without prior COVID-19 infection. Between-group
comparisons of dichotomous categorical outcomes
are analyzed using a chi-square test; where sample
sizes are small, Fisher’s exact test is used instead.
Between-group comparisons are presented alongside
p-values to demonstrate statistical signiﬁcance.
We also aimed to quantify the effects of gender, age,
medical comorbidities, employment, history of
COVID-19 infection, following infection prevention
precautions, MS subtype, current DMT, and DMT
changes on whether a participant will receive a
COVID-19 vaccine. Univariate analyses are performed
for each variable using a chi-square test as above.
Relationships between independent variables and
whether a participant will receive a COVID-19
vaccine are expressed as odds ratios and are presented
alongside 95% conﬁdence intervals and p-values. For
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Table 1. Demographics.a
n
Age, years - median (IQR)
Female - no. (%)
Pregnant/postpartum - no. (%)b
Race/ethnicity - no. (%)
White
Black
Asian
Other
Ethnicity - no. (%)
Hispanic or Latino
Comorbid medical conditions - no. (%)c
0
1
2 or more
MS subtype - no. (%)
RRMS
CIS
SPMS
PPMS
Unclear
Active disease - no. (%)d
Current DMT - no. (%)e
Low-risk
High-risk
Untreated
Conﬁrmed COVID infection - no. (%)f
Required hospital admission/supplemental oxygen
Disposition
Home
Skilled nursing facility/inpatient rehab
COVID infection outcome
Fully recovered
Recovered with complications
Improving
Worsening
Social behaviors - no. (%)g
Social distancing (leaving home less than before pandemic)
Wearing a mask at least some of the time
Maintaining 6 feet of separation when out

237
53.4 (43.7-63.0)
188 (79.3%)
1 (0.5%)
224 (94.5%)
10 (4.2%)
2 (0.8%)
1 (0.4%)
6 (2.5%)
96 (40.5%)
92 (38.8%)
49 (20.7%)
163 (68.8%)
1 (0.4%)
50 (21.1%)
14 (5.9%)
9 (3.8%)
40 (16.9%)
88 (37.1%)
107 (45.1%)
41 (17.3%)
34 (14.3%)
2 (5.9%)
2 (100%)
0 (0%)
18 (52.9%)
11 (32.4%)
4 (11.8%)
1 (2.9%)
206 (92.4%)
218 (97.8%)
211 (94.6%)

a

Percentages given reﬂect proportion responding to question.
Currently pregnant or had given birth in the past 6 weeks at time of baseline survey.
c
Including BMI >30, current smoker, chronic lung disease, heart disease, stroke, diabetes, hypertension, chronic liver
disease, chronic kidney disease, cancer, history of organ transplant, HIV, and other systemic inﬂammatory disease.
d
Deﬁned as at least one relapse in the 12 months preceding the baseline survey or during the survey period.
e
Low-risk DMT deﬁned as interferons, glatiramer acetate, teriﬂunomide, fumarates. High-risk DMT deﬁned as S1P
receptor modulators, B cell depleting agents, cladribine, natalizumab, alemtuzumab.7,19
f
Deﬁned as positive COVID-19 test at any point.
g
At time of baseline survey.
b
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multivariable analyses, a logistic regression model was
developed and is also presented to assess these relationships. All tested variables are included in the model
using forced entry. These relationships are expressed
as adjusted odds ratios, and are also shown alongside
95% conﬁdence intervals and p-values.
Results
Approximately 1700 patients were invited to participate in the study via direct messaging in the electronic
medical record, phone calls, and/or written ﬂiers in
clinic in which 311 responded (≈18% response rate,
though it is unknown how many recipients of the electronic invitation actually accessed it). Quality control
checks conﬁrmed respondents were followed at our
center with a diagnosis of MS. Of the baseline
survey respondents, 237 (76.2%) had responded to a
follow-up survey including questions on COVID-19
vaccination, comprising this study’s overall sample.
More than half of these participants had completed
a follow-up survey at 8 months following their
initial baseline survey (interquartile range [IQR]:
Month 5 – Month 8).
Study sample demographics are presented in Table 1.
This cohort had an average age of 53.4 years), was
predominantly female (79.3%), and was predominantly white (94.5%). All subtypes of MS were represented, and 16.9% had active disease (at least one
relapse in the 12 months preceding the baseline
survey or at any point during the survey period).
There was a high incidence of conﬁrmed
COVID-19 infection in the study cohort (14.3%),
though few required inpatient admission, and more
than half (52.9%) fully recovered. More than 90%
of respondents followed general infection prevention
precautions at the time of their baseline survey
response, including social distancing (92.4%),
wearing a mask at least some of the time (97.8%),
and maintaining 6 feet of separation when out
(94.6%).
Within this sample of people with MS, the vast majority (87.8%) either received or were planning to
receive a COVID-19 vaccine (Table 2); only 8.0%
were not planning to receive a COVID-19 vaccine,
and the remainder (4.2%) were unsure. Compared to
those who received or were planning to receive the
vaccine, those who were not planning to receive or
were unsure about receiving the vaccine were signiﬁcantly less likely to be worried about being at greater
risk of catching COVID-19 (58.2% received/planning
to receive vs. 31.0% not planning/unsure; p=0.004) or
suffering more complications from COVID-19
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infection (73.7% vs. 31.0%; p<0.001). Conversely,
those who were not planning to receive the vaccine
were more worried about MS worsening than
COVID-19 (50.0% vs. 69.0%; p=0.03), and more
wary of vaccine safety/side effects (34.1% vs.
93.1%; p<0.001). The primary concern among those
not planning to receive the vaccine was its long-term
safety (38.0% vs. 70.4%; p=0.004). Concerns about
vaccine efﬁcacy due to a participant’s DMT were
more common in those who received or were planning to receive the vaccine (37.8% vs. 20.7%;
p=0.001).
Of those who had already received a COVID-19
vaccine (Table 3), the majority received mRNA vaccines (57.7% Pﬁzer-BioNTech, 34.6% Moderna),
and of those, more than 90% had completed the
two-dose series. 15.0% held or delayed a dose of
their DMT for vaccination, the majority of whom
were on high efﬁcacy drugs (41.7% ocrelizumab,
16.7% natalizumab). Some participants felt that their
MS symptoms worsened after their ﬁrst/only (7.6%)
or second (14.7%) doses. Side effects from the injections were common (76.1% ﬁrst/only dose, 82.7%
second dose) but short-lived, with a median of 2
days duration following either dose. Most side
effects were mild (80.0% ﬁrst/only dose, 55.3%
second dose); side effects preventing participants
from performing their usual activities were uncommon (1.3% ﬁrst/only dose, 17.7% second dose).
Univariate odds ratios and adjusted odds ratios from
the logistic regression model are presented in
Table 4. Low numbers of minority respondents and
those who had changed their DMT dosing/frequency
precluded these variables from inclusion in the model;
all patients in these categories received or planned to
receive a COVID-19 vaccine. After adjusting for the
other variables listed in Table 4, having 2 or more
medical comorbidities predisposing to worse
COVID-19 outcomes was associated with 5.2-fold
greater odds of receiving a vaccine (adjusted odds
ratio [aOR]=5.2; p=0.04; 95% conﬁdence interval
[CI]: 1.1 to 25.7). With the same adjustments, following recommended infection prevention precautions
was associated with 6.3-fold greater odds of receiving a COVID-19 vaccine (aOR=6.3; p=0.008; 95%
CI: 1.6 to 24.9). Having untreated MS was associated with signiﬁcantly lower adjusted odds of
receiving a vaccine (aOR=0.1; p=0.003; 95% CI:
0.0 to 0.4). Female sex (aOR=3.4; p=0.06; 95%
CI: 1.0 to 11.6) and a progressive MS subtype
(aOR=5.3; p=0.05; 95% CI: 1.0 to 29.0) trended
towards a higher likelihood of getting a vaccine,

www.sagepub.com/msjetc
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Not planning to receive COVID-19 vaccine - no. (%)
Unsure about receiving COVID-19 vaccine - no. (%)

Received/planning to receive COVID-19 vaccine - no. (%)

119
(52.7%)
139
(58.6%)
98
(41.4%)
46
(46.9%)
32
(32.7%)
31
(31.6%)
46
(46.9%)
6 (6.1%)
7 (7.1%)
74
(37.4%)

237
130
(57.5%)
155
(68.6%)
5 (2.1%)

237
208
(87.8%)
19 (8.0%)
10 (4.2%)
Total

b

Percentages given reﬂect proportion responding to question.
Includes those not planning to receive vaccine or unsure about receiving vaccine.
c
Participants able to give more than one answer; percentages may not add to 100%.
d
Among those currently on a disease-modifying therapy.

a

about a possible allergy to vaccine or its components
other concerns
Concerns about COVID-19 vaccine effectiveness because of DMT
- no. (%)d

about long-term safety

about short-term side effects

because of my DMT

because I have MS

Concerns about COVID-19 vaccine safety/side effects… - no. (%)c

n
Worried about being at greater risk of COVID-19 due to MS and/or
DMT - no. (%)
Worried about having more complications from COVID-19 due to
MS and/or DMT - no. (%)
Switched/stopped DMTs speciﬁcally to prevent COVID-19 - no.
(%)
More worried about MS worsening than risk of COVID-19 - no.
(%)
No concerns about COVID-19 vaccine safety/side effects - no. (%)

n

Table 2. Attitudes towards COVID-19 and vaccination.a

3 (4.2%)
2 (2.8%)
68 (37.8%)

27 (38.0%)

25 (35.2%)

26 (36.6%)

34 (47.9%)

71 (34.1%)

3 (11.1%)
5 (18.5%)
6 (20.7%)

19 (70.4%)

6 (22.2%)

6 (22.2%)

12 (44.4%)

27 (93.1%)

2 (6.9%)

137 (65.9%)

1 (3.4%)

4 (1.9%)

20 (69.0%)

9 (31.0%)

146 (73.7%)

99 (50.0%)

Not planning to receive
vaccineb
29
9 (31.0%)

Received/planning to
receive vaccine
208
121 (58.2%)

0.342
0.016
0.001

0.004

0.217

0.174

0.760

<0.001

<0.001

0.034

0.765

<0.001

0.004

p-value
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but were not statistically signiﬁcant in the ﬁnal
adjusted model.
Discussion
In this observational survey of people with MS, we
found that the vast majority of respondents have
received or are planning to receive the COVID-19
vaccine. More people with MS in our survey were
concerned about being at a greater risk for
COVID-19 due to MS/DMT than safety and side
effects of the vaccine. Transient worsening of MS
symptoms was more common after the second dose
(for two-dose vaccines), but was only reported by
15% of participants. As in the general population,
side effects to the vaccine were relatively
common, but the majority were mild and shortlived. Participants who were concerned about
being at higher risk for COVID-19 (either due to
other comorbidities or being on a DMT) and those
who followed infection prevention precautions at
the time of the baseline survey were more willing
to get the vaccine. Less than 40% of participants
were concerned about vaccine effectiveness
because of their DMT, though many of the survey
responses were recorded before recent publications
on the impact of DMTs and other immunosuppressant medications on COVID-19 vaccine
efﬁcacy.20,21
Vaccine hesitancy threatens the progress that has been
made in combating the COVID-19 pandemic in the
United States. Vaccine willingness questions in this
study were answered on follow-up surveys administered between March and May of 2021. It is encouraging to see that 87.8% of participants in this study
are willing to receive one of these vaccines. Other
studies of COVID-19 vaccine willingness in people
with MS suggested rates of vaccine willingness of
66.0% (conducted April 2020 to May 2020)14 and
70.1% (conducted December 2020 to January
2021).11 Though the exact questions and populations
differed amongst these studies, the suggested positive
trajectory of vaccine acceptance over time may reﬂect
greater COVID-19 concern following the winter 2020
pandemic spike in the United States, FDA emergency
use authorization of the vaccines, recommendations
from professional bodies such as the NMSS (ﬁrst published in January 2021), and/or increasing societal
familiarity with the vaccines over time. These
studies collectively show that people with MS are
largely willing to receive the vaccine, perhaps reﬂecting concerns over their COVID-19 risk given their
diagnosis, DMT, and/or comorbidities. Indeed, more
than half of participants in this study are concerned
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about the interactions between COVID-19, MS, and
their DMT. These interactions are complex: factors
associated with MS, such as subtype and disability
status, may affect an individual’s risk of suffering a
worse outcome from COVID-19,7,25,26 and may also
inﬂuence decision-making on DMTs, some of which
may also affect these risks.27 Harboring these concerns also appears to be signiﬁcantly associated with
COVID-19 vaccine willingness in our study.
Reported concerns regarding COVID-19 vaccination
and MS suggest an important and ongoing role for
improved patient education. Vaccine safety has been
the predominant concern in prior studies of
COVID-19 vaccine perspectives amongst people
with MS,11 and substantial minorities of participants
in this study report concerns over vaccine safety
and/or side effects, despite agreement amongst professional organizations that COVID-19 vaccines are
safe for people with MS and safe to use with
DMTs.16,17 Systemic side effects such as pain at the
injection site, fatigue, headaches, and myalgias following COVID-19 vaccination are relatively
common in this cohort and are similar to those
observed in the general population, including in
terms of duration and severity.28,29 Furthermore,
only 15% of participants experienced transient worsening of their MS symptoms following vaccination,
which should reassure people who have concerns
about how the COVID-19 vaccine may exacerbate
their symptoms. Messaging targeting those remaining
unvaccinated should focus on vaccine safety, and the
short duration of predominantly mild side effects
observed in this study may additionally lessen the
degree of perceived vaccination risk amongst this
group.
Some DMTs can diminish humoral immune
responses to COVID-19 vaccination,20 which may
leave some vaccinated individuals under-protected
or unprotected against COVID-19. However, in this
study, fewer participants expressed concern that
their DMT could reduce the vaccine’s effectiveness
than the number taking a high-risk DMT. Of the 58
participants taking a B cell depleting therapy (ocrelizumab, ofatumumab, or rituximab), 10 (17.2%)
reported an adjustment in their dosing regimen (e.g.,
holding or delaying an infusion or injection).
Though there is a mechanistic rationale for holding
a B cell depleting agent to allow B cells to repopulate
prior to vaccination, clinical evidence to support this
strategy is lacking,20 and future studies evaluating
both humoral and cellular immune responses in
people with MS on varying degrees of B cell
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Table 3. Experiences with COVID-19 vaccination.
Manufacturer - no. (%)
Pﬁzer-BioNTech
Received both doses
Days between doses - mean (SD)
Moderna
Received both doses
Days between doses - mean (SD)
Johnson & Johnson
Unsure/no response
Held/delayed DMT dose for the vaccine - no. (%)a
Interferons
Ocrelizumab
Natalizumab
MS symptom worsening after vaccination - no. (%)
No vaccine side effects - no. (%)
Vaccine side effects - no. (%)
Pain in the arm at injection site
Swelling in the arm at injection site
Fever
Chills
Tiredness
Headache
Muscle aches
Lightheadedness
Rash
Nausea/vomiting
Diarrhea
Swollen or sore lymph nodes
Allergic reaction
Other
Duration of side effects, days - median (IQR)
Severity of side effects - no. (%)
Mild (not interfering with daily activities)
Moderate (interfering with daily activities)
Severe (unable to perform usual activities or missed work)

120 (57.7%)
113 (95.0%)
21.5 (3.7)
72 (34.6%)
65 (90.3%)
29.5 (3.7)
9 (4.3%)
7 (3.7%)
24 (15.0%)
10 (41.7%)
10 (41.7%)
4 (16.7%)
After ﬁrst doseb
15 (7.6%)
48 (23.9%)
153 (76.1%)
144 (71.6%)
19 (9.5%)
9 (4.5%)
11 (5.5%)
60 (29.9%)
38 (18.9%)
27 (13.4%)
4 (2.0%)
2 (1.0%)
3 (1.5%)
0 (0%)
3 (1.5%)
0 (0%)
6 (3.0%)
2 (1-3)

After second dose
26 (14.7%)
31 (17.3%)
148 (82.7%)
119 (66.5%)
20 (11.2%)
33 (18.4%)
39 (21.8%)
87 (48.6%)
65 (36.3%)
57 (31.8%)
17 (9.5%)
3 (1.7%)
15 (8.4%)
4 (2.2%)
4 (2.2%)
0 (0%)
12 (6.7%)
2 (1-3)

120 (80.0%)
28 (18.7%)
2 (1.3%)

78 (55.3%)
38 (27.0%)
25 (17.7%)

a

Among those currently on a disease-modifying therapy.
First dose of mRNA vaccine, or single dose of other vaccines.

b

depleting therapy, both in terms of duration from last
infusion and total time on drug, are sorely needed.21
Several respondents also made adjustments in their
dosing regimen of interferons, which should not
impact the response to COVID-19 vaccination;19
this may reﬂect personal patient concerns over
getting multiple injections or “stacking” of ﬂu-like
side effects from both their DMT and the
COVID-19 vaccine. Decisions on whether to hold
or delay a DMT dose should be made by an experienced physician, should be individualized, and

www.sagepub.com/msjetc

should take into consideration the individual’s clinical
characteristics as well as their risk of COVID-19
infection. Outstanding questions on the effects of
DMTs on COVID-19 vaccine efﬁcacy provide
another opportunity for patient education and counseling on the importance of continuing to follow standard infection prevention precautions, even after
vaccination, especially if treated with a cell-depleting
medication such as ocrelizumab, ofatumumab, or
alemtuzumab, or an S1P receptor modulator (ﬁngolimod, siponimod, ozanimod, ponesimod).21
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Table 4. Univariate and adjusted odds ratios for receiving or planning to receive COVID-19 vaccine.
Univariate
OR
Sex
Male
Female
Age
Under 60 years
old
60+ years old
Medical
comorbiditiesa
0
1
2 or more
Employment
Standard risk
employment
High risk
employmentb
Loss of
employment
during pandemic
Not employed
prior to/during
pandemic
Conﬁrmed
COVID-19
infectionc
No
Yes
Following
infection
prevention
precautionsd
No
Yes
MS subtype
Relapsing MS
(CIS, RRMS)
Progressive MS
(SPMS, PPMS)
Current DMT
Low-risk
High-risk
Untreated
Stopped/switched
DMT during
pandemic
No

†
3.262

95% CI

1.437-7.407

P-value

Adjusted
OR

0.005

†
3.355

†

95% CI

P-value

0.975-11.551

0.055

†

2.162

0.843-5.545

0.109

1.261

0.324-4.905

0.737

†
1.138
2.618

0.496-2.611
0.715-9.588

0.760
0.146

†
2.205
5.222

0.706-6.880
1.061-25.693

0.173
0.042

†

†

0.726

0.238-2.211

0.573

0.703

0.175-2.828

0.620

1.517

0.277-8.310

0.631

0.803

0.121-5.316

0.820

2.933

0.951-9.050

0.061

0.939

0.237-3.720

0.929

†
0.778

0.275-2.201

0.636

†
0.875

0.204-3.744

0.857

†
12.545

4.782-32.914

<0.001

†
6.330

1.610-24.894

0.008

†

†

3.831

1.117-13.139

0.033

5.338

0.983-28.994

0.052

†
1.396
0.456

0.541-3.604
0.169-1.227

0.491
0.120

†
0.706
0.096

0.201-2.481
0.021-0.444

0.587
0.003

†

†
(continued)
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Table 4. Continued.
Univariate
OR
Yes

1.039

95% CI
0.372-2.900

P-value

Adjusted
OR

0.942

0.977

95% CI
0.271-3.527

P-value
0.972

a

Including BMI >30, current smoker, chronic lung disease, heart disease, stroke, diabetes, hypertension, chronic liver
disease, chronic kidney disease, cancer, history of organ transplant, HIV, and other systemic inﬂammatory disease.
b
Deﬁned as active healthcare worker (e.g. nurse, technician, physician, hospital worker), active ﬁrst-line responder (e.g.
police, ﬁreﬁghter, paramedic), active essential worker (e.g. grocery store), or active worker in shelter or prison.
c
Deﬁned as positive COVID-19 test at any point.
d
Deﬁned as social distancing (leaving home less than before the pandemic), wearing a mask at least some of the time, and
maintaining 6 feet of separation when out.
†
Referrant.

Numerous interrelated variables play a role in one’s
decision on whether to receive the COVID-19
vaccine. In this cohort, both following infection prevention precautions and having medical comorbidities are associated with a willingness to get the
vaccine, which suggests a cohort that is more likely
to follow health authority guidelines and medical
advice, and that understands the importance of protective measures and their own degree of risk.
Conversely, and potentially reﬂecting history of
adverse responses or skepticism of medical advice,
being untreated is associated with not receiving the
vaccine, even after adjusting for age (those who are
elderly may be less likely to be on a DMT, but
trended towards receiving the vaccine in the univariate analysis) and other variables. Gender trended
towards being a signiﬁcant predictor of vaccine willingness in the adjusted model, consistent with the
general population in the United States.30 Prior
studies have similarly shown race to be a signiﬁcant
predictor of COVID-19 vaccine willingness in the
general population,30,31,32 but low numbers of minority respondents prevented their inclusion in this
regression model. It is notable that minority respondents (10 Black, 2 Asian, and 1 other) all received
or plan to receive the COVID-19 vaccine.
This study is not without limitations. Survey response
bias may have inﬂuenced multiple variables, including willingness to vaccinate, the proportions of participants with a prior conﬁrmed COVID-19 infection
(e.g., may be more invested in contributing to
research on this subject), those with favorable outcomes from those infections (e.g., those with a poor
outcome who otherwise would have participated
may not be capable of doing so), and demographics
(as this sample skews older). The relatively low
response rate limits the generalizability of the study.
Respondents to the electronic survey invitation may

www.sagepub.com/msjetc

have skewed more technologically savvy or more
engaged in their care. These data were collected
from patients followed at a single center in
St. Louis, Missouri that sees few, if any, uninsured
or state-sponsored insured patients, which may skew
unmeasured variables such as socioeconomic status
and also limit the external validity of the study.
Disability data were also not collected in this study,
which may be associated with the dependent variable
(vaccine willingness) as well as several independent
variables (risk of COVID-19,7 age, DMT, employment). Future studies should dig deeper into why
patients chose to hold or change their DMT for the
COVID-19 vaccine and compare COVID-19
vaccine willingness to willingness to receive other
childhood or travel-related vaccines.
Conclusions
Most people with MS who responded to our survey,
notably those who consider themselves at high risk
for COVID-19, were willing to receive a vaccine.
Vaccine side effects in people with MS were similar
to the general population, and only a minority experienced transient worsening of their MS symptoms.
While more work is being done to understand
vaccine effectiveness in people with MS, respondents
were less concerned about effectiveness and only a
few adjusted their DMT schedule. This study provides reassuring and encouraging data on the
COVID-19 vaccine in people with MS and can help
inform conversations between healthcare providers
and people with MS on this topic.
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